Bharat Parenterals Share Price
Sector: Biotechnology & Drugs
1140.00 +40.00 (3.64%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1085.00
Today’s High
1140.00
52 Week Low
802.00
52 Week High
1870.00
Key Metrics
- Market Cap (In Cr) 785.69
- Beta 1.05
- Div. Yield (%) 0.09
- P/B 2.38
- TTM P/E -
- Sector P/E 22.43
- D/E 0.01
- Open Price 1100
- Prev Close 1100
Bharat Parenterals Analysis
Price Analysis
-
1 Week1.05%
-
3 Months15.44%
-
6 Month-27.57%
-
YTD-22.33%
-
1 Year-24.51%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Bharat Parenterals News
Voltas, Tata Elxsi, Cera Sanitaryware among 6 stocks to trade ex-dividend today
2 min read . 25 Jun 2024Bharat Parenterals Q4 results : loss at ₹0.3Cr, Revenue increased by 33.06% YoY
1 min read . 25 May 2024Bharat Parenterals Q3 FY24 Results Live: Profit Rises by 32.98% YoY
1 min read . 15 Feb 2024Bharat Parenterals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 340.38
- Selling/ General/ Admin Expenses Total
- 49.66
- Depreciation/ Amortization
- 35.32
- Other Operating Expenses Total
- 102.54
- Total Operating Expense
- 373
- Operating Income
- -32.62
- Net Income Before Taxes
- -33.95
- Net Income
- -12.62
- Diluted Normalized EPS
- -66.64
- Period
- 2025
- Total Assets
- 648.53
- Total Liabilities
- 317.86
- Total Equity
- 330.67
- Tangible Book Valueper Share Common Eq
- 402.5
- Period
- 2025
- Cashfrom Operating Activities
- -27.25
- Cashfrom Investing Activities
- -137.11
- Cashfrom Financing Activities
- 156.09
- Net Changein Cash
- -8.27
- Period
- 2024
- Total Revenue
- 257.36
- Selling/ General/ Admin Expenses Total
- 54.79
- Depreciation/ Amortization
- 8.93
- Other Operating Expenses Total
- 5.48
- Total Operating Expense
- 243.26
- Operating Income
- 14.1
- Net Income Before Taxes
- 18.72
- Net Income
- 14.52
- Diluted Normalized EPS
- 25.02
- Period
- 2024
- Total Assets
- 503.82
- Total Liabilities
- 306.56
- Total Equity
- 197.27
- Tangible Book Valueper Share Common Eq
- 337.17
- Period
- 2024
- Cashfrom Operating Activities
- -4.71
- Cashfrom Investing Activities
- -104.78
- Cashfrom Financing Activities
- 110.43
- Net Changein Cash
- 0.94
- Period
- 2023
- Total Revenue
- 217.98
- Selling/ General/ Admin Expenses Total
- 43.94
- Depreciation/ Amortization
- 5.78
- Other Operating Expenses Total
- 3.56
- Total Operating Expense
- 203.77
- Operating Income
- 14.22
- Net Income Before Taxes
- 23.59
- Net Income
- 16.44
- Diluted Normalized EPS
- 27.84
- Period
- 2023
- Total Assets
- 350.34
- Total Liabilities
- 167.55
- Total Equity
- 182.8
- Tangible Book Valueper Share Common Eq
- 316.55
- Period
- 2023
- Cashfrom Operating Activities
- 21.66
- Cashfrom Investing Activities
- -77.82
- Cashfrom Financing Activities
- 60.6
- Net Changein Cash
- 4.44
- Period
- 2022
- Total Revenue
- 212.01
- Selling/ General/ Admin Expenses Total
- 34.78
- Depreciation/ Amortization
- 6.55
- Other Operating Expenses Total
- 3.18
- Total Operating Expense
- 190.43
- Operating Income
- 21.58
- Net Income Before Taxes
- 27.88
- Net Income
- 21.05
- Diluted Normalized EPS
- 37.64
- Period
- 2022
- Total Assets
- 226.06
- Total Liabilities
- 60.23
- Total Equity
- 165.83
- Tangible Book Valueper Share Common Eq
- 287.16
- Period
- 2022
- Cashfrom Operating Activities
- -1.07
- Cashfrom Investing Activities
- -6.63
- Cashfrom Financing Activities
- 9.42
- Net Changein Cash
- 1.72
- Period
- 2021
- Total Revenue
- 204.64
- Selling/ General/ Admin Expenses Total
- 33.05
- Depreciation/ Amortization
- 5.91
- Other Operating Expenses Total
- 3.17
- Total Operating Expense
- 185.36
- Operating Income
- 19.28
- Net Income Before Taxes
- 27.12
- Net Income
- 20.39
- Diluted Normalized EPS
- 35.57
- Period
- 2021
- Total Assets
- 198.65
- Total Liabilities
- 54.78
- Total Equity
- 143.87
- Tangible Book Valueper Share Common Eq
- 251.09
- Period
- 2021
- Cashfrom Operating Activities
- 24.45
- Cashfrom Investing Activities
- -43.37
- Cashfrom Financing Activities
- 10.5
- Net Changein Cash
- -8.43
- Period
- 2020
- Total Revenue
- 227.96
- Selling/ General/ Admin Expenses Total
- 37.43
- Depreciation/ Amortization
- 5.84
- Other Operating Expenses Total
- 2.97
- Total Operating Expense
- 205.67
- Operating Income
- 22.3
- Net Income Before Taxes
- 32.8
- Net Income
- 24.14
- Diluted Normalized EPS
- 42.05
- Period
- 2020
- Total Assets
- 187.5
- Total Liabilities
- 69.31
- Total Equity
- 118.19
- Tangible Book Valueper Share Common Eq
- 206.28
- Period
- 2020
- Cashfrom Operating Activities
- 14.45
- Cashfrom Investing Activities
- -12.6
- Cashfrom Financing Activities
- -2.82
- Net Changein Cash
- -0.96
- Period
- 2019
- Total Revenue
- 219.3
- Selling/ General/ Admin Expenses Total
- 34.91
- Depreciation/ Amortization
- 6.07
- Other Operating Expenses Total
- 5.12
- Total Operating Expense
- 196.72
- Operating Income
- 22.59
- Net Income Before Taxes
- 34.59
- Net Income
- 21.25
- Diluted Normalized EPS
- 36.81
- Period
- 2019
- Total Assets
- 158.93
- Total Liabilities
- 64.92
- Total Equity
- 94.01
- Tangible Book Valueper Share Common Eq
- 164.07
- Period
- 2019
- Cashfrom Operating Activities
- 20.43
- Cashfrom Investing Activities
- -9.36
- Cashfrom Financing Activities
- -3.89
- Net Changein Cash
- 7.18
- Period
- 2025-03-31
- Total Revenue
- 103.98
- Selling/ General/ Admin Expenses Total
- 18.14
- Depreciation/ Amortization
- 8.52
- Other Operating Expenses Total
- 30.08
- Total Operating Expense
- 110.28
- Operating Income
- -6.3
- Net Income Before Taxes
- -8.3
- Net Income
- -4.73
- Diluted Normalized EPS
- -14.4
- Period
- 2025-03-31
- Total Assets
- 648.53
- Total Liabilities
- 317.86
- Total Equity
- 330.67
- Tangible Book Valueper Share Common Eq
- 402.5
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -27.25
- Cashfrom Investing Activities
- -137.11
- Cashfrom Financing Activities
- 156.09
- Net Changein Cash
- -8.27
- Period
- 2024-12-31
- Total Revenue
- 72.26
- Selling/ General/ Admin Expenses Total
- 10.98
- Depreciation/ Amortization
- 8.76
- Other Operating Expenses Total
- 21.96
- Total Operating Expense
- 77.37
- Operating Income
- -5.11
- Net Income Before Taxes
- -5.5
- Net Income
- -1.66
- Diluted Normalized EPS
- -2.57
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 71.63
- Selling/ General/ Admin Expenses Total
- 10.62
- Depreciation/ Amortization
- 9.01
- Other Operating Expenses Total
- 26.97
- Total Operating Expense
- 88.3
- Operating Income
- -16.67
- Net Income Before Taxes
- -15.37
- Net Income
- -7.5
- Diluted Normalized EPS
- -11.51
- Period
- 2024-09-30
- Total Assets
- 541.83
- Total Liabilities
- 258.57
- Total Equity
- 283.26
- Tangible Book Valueper Share Common Eq
- 432.33
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -21.86
- Cashfrom Investing Activities
- -40.54
- Cashfrom Financing Activities
- 62.3
- Net Changein Cash
- -0.23
- Period
- 2024-06-30
- Total Revenue
- 92.51
- Selling/ General/ Admin Expenses Total
- 9.92
- Depreciation/ Amortization
- 9.03
- Other Operating Expenses Total
- 23.53
- Total Operating Expense
- 97.05
- Operating Income
- -4.54
- Net Income Before Taxes
- -4.77
- Net Income
- 1.27
- Diluted Normalized EPS
- 2.2
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 67.82
- Selling/ General/ Admin Expenses Total
- 6.64
- Depreciation/ Amortization
- 3.87
- Other Operating Expenses Total
- 16.13
- Total Operating Expense
- 70.69
- Operating Income
- -2.87
- Net Income Before Taxes
- -1.36
- Net Income
- -0.3
- Diluted Normalized EPS
- -0.51
- Period
- 2024-03-31
- Total Assets
- 503.82
- Total Liabilities
- 306.56
- Total Equity
- 197.27
- Tangible Book Valueper Share Common Eq
- 337.17
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -4.71
- Cashfrom Investing Activities
- -104.78
- Cashfrom Financing Activities
- 110.43
- Net Changein Cash
- 0.94
- Period
- 2023-12-31
- Total Revenue
- 59.82
- Selling/ General/ Admin Expenses Total
- 5.31
- Depreciation/ Amortization
- 1.82
- Other Operating Expenses Total
- 11.28
- Total Operating Expense
- 55.03
- Operating Income
- 4.79
- Net Income Before Taxes
- 5.47
- Net Income
- 3.79
- Diluted Normalized EPS
- 6.45
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Bharat Parenterals Technical
Moving Average
SMA
- 5 Day1118.31
- 10 Day1144.72
- 20 Day1213.32
- 50 Day1119.24
- 100 Day1084.73
- 300 Day1312.18
Bharat Parenterals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Wanbury
- 285.2
- 9.8
- 3.56
- 330
- 151.1
- 935.97
- Kopran
- 185.55
- 0.55
- 0.3
- 369.2
- 157
- 898.85
- Bharat Parenterals
- 1140
- 40
- 3.64
- 1870
- 802
- 785.69
- Shree Ganesh Remedies
- 601.95
- -9.8
- -1.6
- 950.05
- 600
- 771.03
- Kilitch Drugs India
- 426.75
- -9.65
- -2.21
- 500.05
- 271.3
- 686.31
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Wanbury
- 31.59
- 15.69
- -
- 5.62
- Kopran
- 23.21
- 1.73
- 12.24
- 8.66
- Bharat Parenterals
- -
- 2.38
- 6.54
- 1.93
- Shree Ganesh Remedies
- 33.49
- 5.32
- 21.94
- 20.52
- Kilitch Drugs India
- 25.85
- 3.41
- 8.32
- 8.41
Bharat Parenterals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-May-25
- Audited Results & Final Dividend
- 03-Feb-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 10-Jun-24
- Preferential issue of shares
- 05-Jun-24
- A.G.M.
- 22-May-24
- Audited Results
- 29-Apr-24
- Preferential issue of shares
- 13-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 07-Oct-24
- 06-Sept-24
- POM
- 02-Jul-24
- 10-Jun-24
- AGM
- 30-Sept-23
- 08-Sept-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-May-25
- -
- -
- 1
- 10-Jun-24
- 25-Jun-24
- 25-Jun-24
- 1
- 22-May-23
- 25-Sept-23
- 25-Sept-23
- 0.75


